SAB Biotherapeutics Q1 2024 GAAP EPS $(0.43) Beats $(0.96) Estimate
SAB Biotherapeutics Q1 2024 GAAP EPS $(0.43) Beats $(0.96) Estimate
SAB Biotherapeutics 2024年第一季度GAAP每股收益美元（0.43美元）超过预期（0.96美元）
SAB Biotherapeutics (NASDAQ:SABS) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.96) by 55.21 percent. This is a 186.67 percent decrease over losses of $(0.15) per share from the same period last year.
SAB Biotherapeutics（纳斯达克股票代码：SABS）公布的季度亏损为每股0.43美元，比分析师普遍预期的0.96美元（0.96美元）高出55.21％。这比去年同期每股亏损0.15美元（0.15美元）下降了186.67％。
SAB reaffirms it has sufficient cash, assuming the receipt of funds upon the exercise of all outstanding Tranche B warrants, that is expected to be sufficient to fund its operations into 2026.
SAB重申，假设在行使所有未偿还的B批认股权证后获得资金，则有足够的现金，预计足以为其2026年的运营提供资金。